USP28-IN-3

Cat. No.:	HY-149229
CAS No.:	2931509-14-5
Molecular Formula:	$C_{23}H_{20}Cl_2N_2O_3S$
Molecular Weight:	475.39
Target:	Deubiquitinase
Pathway:	Cell Cycle/DNA Damage
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.



BIOLOGICAL ACTIVITY

Description	USP28-IN-3 is a USP28 inhibitor (IC_{50}=0.1 μM) with high selectivity over USP2, USP7, USP8, USP9x, UCHL3 and UCHL5. USP28-IN-3 shows cytotoxicity against cancer cells, down-regulates the cellular level of c-Myc through ubiquitin-proteasome system. USP28-IN-3 also decreases the ankyrase-1/2 level in vitro. USP28-IN-3 enhance the sensitivity of colorectal cancer cells to Regorafenib (HY-10331)[1].
IC_{50} & Target	USP28 0.1 μM (IC_{50})
In Vitro	USP28-IN-3 (compound 9o) (10 μM, 15 μM; 3 d) inhibits colony formation of human colorectal cancer cells HCT116 (15 μM) and Ls174T (10 μM)[1]. USP28-IN-3 (20-80 μM; 24 h) down-regulates the level of c-Myc by enhancing its degradation via ubiquitin-proteasome system (UPS)[1]. MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Western Blot Analysis[1]

Cell Line:	Human colorectal cancer cells HCT116 and Ls174T
Concentration:	20 μM, 30 μM, 50 μM, and 60 μM, for Ls174T; 30 μM, 50 μM, 60 μM and 80 μM for HCT116
Incubation Time:	24 h
Result:	Dose-dependently down-regulated the cellular level of c-Myc.

REFERENCES

[1]. Zhou D, et al. Structure-based discovery of potent USP28 inhibitors derived from Vismodegib. Eur J Med Chem. 2023 Jun 5;254:115369.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@MedChemExpress.com
Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA